{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T07:17:40Z","timestamp":1781421460164,"version":"3.54.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["BERING21AO"],"award-info":[{"award-number":["BERING21AO"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jcf.2023.11.015","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T07:08:10Z","timestamp":1701328090000},"page":"519-523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Preliminary evidence for sustained efficacy of CFTR modulator therapy with concomitant rifabutin administration"],"prefix":"10.1016","volume":"23","author":[{"given":"Eunjin","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4249-6115","authenticated-orcid":false,"given":"Sarah M.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7860-6625","authenticated-orcid":false,"given":"Lynn","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia H.","family":"Eshaghian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3744-3310","authenticated-orcid":false,"given":"Paul M.","family":"Beringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10212","key":"10.1016\/j.jcf.2023.11.015_bib0001","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2023.11.015_bib0002","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jcf.2023.11.015_bib0003","doi-asserted-by":"crossref","DOI":"10.1111\/jcpt.13329","article-title":"A current review of the safety of cystic fibrosis transmembrane conductance regulator modulators","volume":"46","author":"Gavioli","year":"2021","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"10.1016\/j.jcf.2023.11.015_bib0004","doi-asserted-by":"crossref","DOI":"10.1111\/cts.12610","article-title":"Pharmacokinetic and drug-drug interaction profiles of the combination of tezacaftor\/ivacaftor","volume":"12","author":"Garg","year":"2019","journal-title":"Clin Transl Sci"},{"issue":"1","key":"10.1016\/j.jcf.2023.11.015_bib0005","doi-asserted-by":"crossref","DOI":"10.2174\/1872312812666180328105259","article-title":"Cytochrome P450 3A4 induction: lumacaftor versus ivacaftor potentially resulting in significantly reduced plasma concentration of ivacaftor","volume":"12","author":"Schneider","year":"2018","journal-title":"Drug Metab Lett"},{"key":"10.1016\/j.jcf.2023.11.015_bib0006","series-title":"Vertex pharmaceuticals inc","year":"2019"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2023.11.015_bib0007","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-207360","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis","volume":"71","author":"Floto","year":"2016","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.jcf.2023.11.015_bib0008","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jcf.2023.11.015_bib0009","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1086\/514748","article-title":"A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex","volume":"28","author":"Gordin","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jcf.2023.11.015_bib0010","doi-asserted-by":"crossref","DOI":"10.1513\/AnnalsATS.201604-246OC","article-title":"Macrolide-resistant mycobacterium avium complex lung disease: analysis of 102 consecutive cases","volume":"13","author":"Morimoto","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"8","key":"10.1016\/j.jcf.2023.11.015_bib0011","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1128\/AAC.06282-11","article-title":"Effect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-O-desacetyl-rifabutin in healthy subjects","volume":"56","author":"Vourvahis","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.jcf.2023.11.015_bib0012","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01104-22","article-title":"Physiologically based pharmacokinetic modeling to guide management of drug interactions between elexacaftor-tezacaftor-ivacaftor and antibiotics for the treatment of nontuberculous mycobacteria","volume":"66","author":"Hong","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcf.2023.11.015_bib0013","series-title":"Annual data report","year":"2020"},{"issue":"4","key":"10.1016\/j.jcf.2023.11.015_bib0014","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/phar.2786","article-title":"Safety of elexacaftor\/tezacaftor\/ivacaftor dose reduction: mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series","volume":"43","author":"Hong","year":"2023","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jcf.2023.11.015_bib0015","unstructured":"U.S. Food and Drug Administration. Center for drug evaluation and research. multi-discipline review, Elexacaftor\/Tezacaftor\/Ivacaftor."},{"key":"10.1016\/j.jcf.2023.11.015_bib0016","series-title":"Assessment report for tezacaftor\/ivacaftor","year":"2018"},{"issue":"5","key":"10.1016\/j.jcf.2023.11.015_bib0017","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1002\/ppul.23971","article-title":"Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer","volume":"53","author":"Guimbellot","year":"2018","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.jcf.2023.11.015_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11060458","article-title":"Does one dose fit all?","volume":"11","author":"van der Meer","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.jcf.2023.11.015_bib0019","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.26093","article-title":"Plasma and cellular ivacaftor concentrations in patients with CF","author":"Guimbellot","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.jcf.2023.11.015_bib0020","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.117.077834","article-title":"Evaluation of clinical drug interaction potential of clofazimine using static and dynamic modeling approaches","volume":"46","author":"Sangana","year":"2018","journal-title":"Drug Metab Dispos"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323017216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323017216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:14:59Z","timestamp":1778620499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323017216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1569199323017216"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.11.015","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preliminary evidence for sustained efficacy of CFTR modulator therapy with concomitant rifabutin administration","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}